PreprintArticleVersion 1This version is not peer-reviewed
Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis
Version 1
: Received: 3 July 2024 / Approved: 3 July 2024 / Online: 4 July 2024 (14:50:49 CEST)
How to cite:
Chiner, E.; Murcia, M.; Boira, I.; Bernabeu, M. Á.; Esteban, V.; Martínez-Moragón, E. Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis. Preprints2024, 2024070402. https://doi.org/10.20944/preprints202407.0402.v1
Chiner, E.; Murcia, M.; Boira, I.; Bernabeu, M. Á.; Esteban, V.; Martínez-Moragón, E. Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis. Preprints 2024, 2024070402. https://doi.org/10.20944/preprints202407.0402.v1
Chiner, E.; Murcia, M.; Boira, I.; Bernabeu, M. Á.; Esteban, V.; Martínez-Moragón, E. Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis. Preprints2024, 2024070402. https://doi.org/10.20944/preprints202407.0402.v1
APA Style
Chiner, E., Murcia, M., Boira, I., Bernabeu, M. Á., Esteban, V., & Martínez-Moragón, E. (2024). Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis. Preprints. https://doi.org/10.20944/preprints202407.0402.v1
Chicago/Turabian Style
Chiner, E., Violeta Esteban and Eva Martínez-Moragón. 2024 "Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis" Preprints. https://doi.org/10.20944/preprints202407.0402.v1
Abstract
Background: The objective of this study was to evaluate, the clinical benefit of benralizumab in patients with uncontrolled severe asthma associated with chronic rhinosinusitis with nasal polyposis (CRSwNP).
Methods: The study included patients with uncontrolled severe asthma associated with CRSwNP who started therapy with benralizumab. Pulmonary function, eosinophilia, IgE, comorbidity, changes in the Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Visual Analogue Scale (VAS), Quality of Life (AQLQ), VAS (obstruction, drip, anosmia, facial pressure), SNOT-22, decrease or withdrawal of steroids and other medication, hospital admissions and emergency visits were analysed. The FEOS scale and EXACTO were employed in the assessment of response.
Results: We analyzed 58 patients who completed minimal treatment at 12 months. After treatment with benralizumab, exacerbations were reduced by 82% (p
Keywords
Asthma; benralizumab; polyposis; rhinosinusitis
Subject
Medicine and Pharmacology, Pulmonary and Respiratory Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
